Publications by authors named "R Winzenrieth"
Advanced 3D-DXA insights into bone density changes in hyperparathyroidism.
J Diabetes Metab Disord
December 2024
Article Synopsis
- Primary hyperparathyroidism (PHPT) leads to increased parathyroid hormone levels, resulting in bone density loss and changes in bone structure, particularly affecting the femur's trabecular and cortical compartments.
- A retrospective study analyzed 74 Caucasian Italian patients with PHPT using 3D imaging to measure bone mineral density and thickness from 2011 to 2016, revealing negative effects on both cortical and trabecular volumetric bone densities.
- Results indicate that while PHPT negatively impacts both types of bone density, cortical thickness remains largely unaffected, aligning with existing literature on the condition's effects on bone health.
Background: Low hip bone mineral density (BMD) in patients who undergo total hip arthroplasty (THA) increases the risk of periprosthetic fractures, implant instability, and other complications. Recently, emphasis has been placed on bone health optimization: treating low BMD prior to a planned orthopaedic implant procedure in an effort to normalize BMD and reduce the potential risk of future complications. Abaloparatide is a U.
View Article and Find Full Text PDFContext: Hypercortisolism frequently induces trabecular bone loss, more pronounced at the lumbar spine, resulting in osteoporosis, and thus an increase in fracture risk. Several studies have shown bone mass recovery in patients with Cushing's disease (CD) after treatment.
Objective: To examine treatment effects on TBS (trabecular bone score) in addition to aBMD (areal bone mineral density) in a cohort of patients with CD.
Romosozumab treatment in women with postmenopausal osteoporosis increases bone formation while decreasing bone resorption, resulting in large BMD gains to reduce fracture risk within 1 yr. DXA-based 3D modeling of the hip was used to assess estimated changes in cortical and trabecular bone parameters and map the distribution of 3D changes in bone parameters over time in patients from 2 randomized controlled clinical trials: FRAME (romosozumab vs placebo followed by denosumab) and ARCH (romosozumab vs alendronate followed by alendronate). For each study, data from a subset of ~200 women per treatment group who had TH DXA scans at baseline and months 12 and 24 and had provided consent for future research were analyzed post hoc.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to evaluate bone mineral density (BMD) and quality in patients with psoriasis (PsO) and psoriatic arthritis (PsA) by comparing them with matched control subjects.
- Methods involved analyzing bone density through dual-energy X-ray absorptiometry (DXA) and assessing bone quality using trabecular bone score (TBS) and 3D DXA analysis.
- Results indicated that while patients with PsA had normal bone parameters, those with PsO showed higher femoral neck BMD but decreased bone texture, suggesting a possible risk for impaired vertebral bone resistance despite no increased risk for hip fractures.